Medivir Strengthens its Management Team

Huddinge, Sweden - Medivir AB (OMX: MVIR), an emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces several new appointments to its executive management team.

Ron Long, CEO of Medivir commented, “These appointments will support Medivir as it continues to progress its research and commercial capabilities and will provide the company with a stronger operational and strategic management team to develop Medivir’s existing R&D projects and marketed products”.

Dr Maris Hartmanis has been appointed to Medivir’s management team as deputy CEO and COO (Chief Operating Officer). In parallel to this appointment Maris Hartmanis will continue to work as CEO of Biophausia, the specialty pharmaceutical company which recently was acquired by Medivir. Maris Hartmanis has extensive experience of the pharmaceutical industry, most notably holding senior positions at Gambro, Amersham and Pharmacia.

Professor Bertil Samuelsson has been appointed CSA (Chief Scientific Advisor). Bertil Samuelsson previously held the position of CSO (Chief Scientific Officer) and will leave the operational management team to focus his efforts on the strategic development of Medivir’s R&D, including new project opportunities.

Medivir also names Dr Charlotte Edenius as Executive VP Research & Development. In her new role she will assume the operational responsibilities for Medivir’s Research and Development. Charlotte Edenius currently holds the position as VP Research & Development projects at Medivir.

In order to strengthen Medivir’s capabilities in clinical development Dr Jens D. Kristensen has been recruited as Executive VP Clinical to head the clinical unit at Medivir. Prior to joining Medivir Jens Kristensen most recently served as Vice President Clinical Development at Karo Bio and also has experience working at AstraZeneca within clinical development.

For more information about Medivir, please contact:

About MedivirMedivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is TMC435, a novel protease inhibitor is in phase 3 clinical development for hepatitis C and is partnered with Tibotec Pharmaceuticals. In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialization of TMC435 in the Nordic markets, once approved.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear® was launched on the US market in February 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe is partnered with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico have recently been sold to Meda AB. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company’s website: www.medivir.com.

Tags: